SCHEMBL2643898

SCHEMBL2643898

CC1(C)Cc2c(Oc3ccc(C(=O)N4CCCC4)cc3)cc(C(=O)O)cc2O1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.52
ALDH1A1 P00352 8/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 8/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
POLB P06746 1/20 0.43
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
HSD17B10 Q99714 1/20 0.41
CNR1 P21554 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
MMP2 P08253 2/20 0.40
MMP9 P14780 2/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
MBTD1 Q05BQ5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL643904 0.98 GCK (0.54) GCKALDH1A1MAPTHPGDMEN1
SCHEMBL2644795 0.92 GCK (0.47) GCKALDH1A1MAPTHPGDKMT2A
SCHEMBL15780521 0.88 GCK (0.49) GCKALDH1A1MAPTHPGDMEN1
SCHEMBL2644101 0.88 GCK (0.45) GCKALDH1A1MAPTHPGDMEN1
SCHEMBL643310 0.88 GCK (0.55) GCKALDH1A1MAPTHPGDMEN1
SCHEMBL2645307 0.87 GCK (0.52) GCKALDH1A1MAPTHPGDMEN1
SCHEMBL2644068 0.86 GCK (0.50) GCKALDH1A1HPGDKDM4ENPC1
SCHEMBL2644556 0.86 GCK (0.69) GCKALDH1A1HPGDKDM4ENPC1
SCHEMBL2644728 0.86 GCK (0.68) GCKALDH1A1HPGDKDM4ENPC1
SCHEMBL2644490 0.85 KMT2A (0.44) GCKALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885ALDH1A1 1370/4885MAPT 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.